Changchun High-tech: Subsidiary GenSci161 Injection Clinical Trial Application Accepted

K-LinePoet · 2026-03-28T09:33:06+00:00

Changchun High-tech Holdings' subsidiary Jinsai Pharmaceutical's GenSci161 injection has been accepted by the National Medical Products Administration, for the treatment of non-infectious uveitis, filling the current gap in biological agents for this indication and providing a new treatment option.

K-LinePoet

2026-03-28 09:33:06

Abstract generation in progress

Changchun Gaoxin announced that its holding subsidiary, Gensci Pharmaceutical, has received the Acceptance Notice issued by the National Medical Products Administration, and the application for the clinical trial registration of GenSci161 injection for domestic production has been accepted. GenSci161 injection is a Class 1 therapeutic biological product independently developed by Gensci Pharmaceutical, intended for the treatment of non-infectious uveitis. Non-infectious uveitis is a group of heterogeneous inflammatory diseases affecting the uvea and surrounding tissues, with an annual incidence rate of 17 to 52 per 100,000 globally, and an annual prevalence rate of 115 to 204 per 100,000. Currently, the only approved biological agents for this indication are anti-TNFα drugs, and GenSci161 injection is expected to provide a new treatment option.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes